Russel J H, Hale A H, Inbar D, Eisen H N
Eur J Immunol. 1978 Sep;8(9):640-5. doi: 10.1002/eji.1830080907.
It was previously observed that MOPC-315EL, a subline of the BALB/c myeloma tumor MOPC-315, varies in its ability to interact with primary anti-H-2d cytotoxic thymus-derived lymphocytes (CTL) while remaining invariant in its expression of cell surface antigens recognized by anti-H-2d sera. This paper demonstrates (a) that secondary anti-H-2d CTL also fail to recognize the late tumor cells, and (b) that two other CTL systems (anti-minor histocompatibility antigens and anti-2,4,6-trinitrophenyl), which require recognition of both H-2 products and other surface antigens, also fail to react with the late tumor cells. The defect in the late tumor cells was evident when they were used as targets, inhibitors, and stimulators of CTL activity.
先前观察到，BALB/c骨髓瘤肿瘤MOPC-315的亚系MOPC-315EL与原发性抗H-2d细胞毒性胸腺来源淋巴细胞（CTL）相互作用的能力有所不同，而其对抗H-2d血清识别的细胞表面抗原的表达保持不变。本文证明：（a）继发性抗H-2d CTL也无法识别晚期肿瘤细胞；（b）另外两个CTL系统（抗次要组织相容性抗原和抗2,4,6-三硝基苯），它们需要识别H-2产物和其他表面抗原，也无法与晚期肿瘤细胞发生反应。当晚期肿瘤细胞用作CTL活性的靶标、抑制剂和刺激剂时，其缺陷就很明显。
